WEST BEND, Wis., Aug. 8, 2011 /PRNewswire/ — Eurofins Optimed
Clinical Research, an experienced European clinical research
service provider and Spaulding Clinical Research, LLC., US-based,
leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical
Device Manufacturer, announce a joint partnership agreement.
This partnership leverages the strengths of both companies
and facilitates collaboration on integrated clinical services to
engage pharmaceutical clients who demand a global footprint.
“The culture of excellence and research facilities designed to
execute high-quality studies was very impressive to our team.
We felt immediately comfortable with the Optimed clinical
team and witnessed their efficient execution of studies,” states
Daniel Selness, General Manager and Senior Vice President of
Operations. “We were very impressed that Spaulding achieved
ISO certification, which is not common among US clinical research
facilities. Their innovative systems approach with Electronic
Data Capture is something that we have been looking to implement,
so the partnership will allow us to consider how to collaborate
more closely as these systems are put in place,” states Yves
Donazzolo, MD, CEO and President of Optimed.
Eurofins Optimed and Spaulding Clinical offer a full range of
global services to the Pharmaceutical industry and Biotechnology
companies from study design through study execution/conduct, data
management, statistical analysis, and medical writing. Both
companies excel in TQT, first-in-human, multiple rising dose,
bioavailability/bioequivalence, drug interaction, food effect
studies and Proof-Of-Concept studies in patients.
Eurofins Optimed (www.optimed.fr), founded in 1990,
is located in France and provides Phase I- IV clinical
research services. Eurofins Optimed operates 100 beds in two
clinical pharmacology units, in Grenoble and Lyon. Studies in
health
‘/>”/>
